Merck and Moderna report positive topline results for personalized cancer vaccine

A third death was reported in China’s expedited clinical trials, raising safety concerns for fast‑track studies in the region.

Merck and Moderna announced positive topline data from their personalized cancer vaccine programs, indicating that the candidates generated immune responses and met early efficacy benchmarks.

While the initial findings are encouraging, analysts note that longer‑term outcomes and larger trial cohorts are needed to confirm the vaccines’ clinical benefit and safety profile.